• You need to sign in or sign up before continuing.
Close
Announcements
Projects
Orgs
Project Post
Articles 13
Votes 0
Merck.com
U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season - Merck.com
~1mo
Merck Announces Positive Topline Results From the First Two Phase 3 CORALreef Trials Evaluating Enlicitide Decanoate for the Treatment of Adults With Hyperlipidemia - Merck.com
~1mo
Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline - Merck
>1y
The impact of RSV: a father’s story and call for prevention - Merck
>1y
Merck to Acquire Caraway Therapeutics, Inc. - Merck
>1y
Merck Announces Third-Quarter 2023 Financial Results - Merck
>1y
Daiichi Sankyo and Merck Announce Global Development and Commercialization Collaboration for Three Daiichi Sankyo DXd ADCs - Merck
>1y
Merck Announces Pivotal KEYNOTE-671 Trial Meets Dual Primary Endpoint of Overall Survival (OS) in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC) - Merck
>1y
Merck's KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Muscle-Invasive Urothelial Carcinoma (MIUC) After Surgery - Merck
almost2y
Merck Announces Second-Quarter 2023 Financial Results - Merck
almost2y
Merck Announces First-Quarter 2023 Financial Results - Merck
~2y
Merck Provides Update on Phase 3 MOVe-AHEAD Trial Evaluating LAGEVRIO™ (molnupiravir) for Post-exposure Prophylaxis for Prevention of COVID-19 - Merck
>2y
Merck Announces Second-Quarter 2022 Financial Results - Merck
almost3y